Boston Scientific Co. said a cyberattack that disrupted its global IT systems for eight days could affect its 2027 growth trajectory, prompting the medical-device maker to revise its organic growth forecast to the lower end of a 2% to 4% range. The company provided more detailed guidance and a full 2027 framework when it holds an earnings call on Oct. 28, 2026.
Mike Mahoney, chairman and CEO, told analysts at Wells Fargo's 21st Annual Healthcare Conference on Sept. 10, 2026, that all IT systems, manufacturing plants, distribution networks and third-party supplier connectivity have been restored. "We just have to sift through what the recapture rate is, and that is still what we are working through now," Mahoney said. A long-range plan update is expected in January 2027.
Shares of Boston Scientific (BSX) traded at $44.96, near its 52-week low of $42.20, having fallen roughly 53% year-to-date as of the conference date. The company's P/E ratio stood at 18.33 and its PEG ratio at 0.38, according to InvestingPro data cited at the conference.
The company also reported that its acquisition of Penumbra remains on track to close by year-end 2026. Penumbra is expected to dilute earnings by $0.06 to $0.08 per share in its first year.
In electrophysiology, Mahoney described the division's turnaround under Boston Scientific ownership. "We had a crappy EP business. Sorry. We had a bad EP business, and now we have a strong number 2 global EP business," he said.
The company estimates its pulsed field ablation market share at approximately 50%, down from a dominant position at launch, though U.S. PFA penetration is nearing 90%. The overall PFA market is still projected to grow at a double-digit rate. The FARAWAVE Ultra device is scheduled for launch in the second half of 2027, alongside a planned defibrillator platform and the EMPOWER leadless pacemaker.
WATCHMAN, the left atrial appendage closure device, continues to hold roughly 90% market share despite headwinds. U.S. procedures are expected to decline mid- to high-single digits year-over-year in the second half of 2026, with a similar market contraction anticipated in 2027. Proposed physician reimbursement cuts of 20% for WATCHMAN were also discussed. Dr. Ken Stein, chief medical officer, emphasized that 30% to 40% of high-risk atrial fibrillation patients in the U.S. and Western Europe remain unprotected against stroke, and that WATCHMAN should be considered for every high-risk patient who cannot take long-term oral anticoagulants.
On the coronary side, Seismic IVL for coronary use was highlighted as a meaningful growth driver expected in 2028, with the broader coronary IVL market already exceeding $1 billion.
About eight new platforms are expected to enter markets totaling more than $25 billion in combined addressable revenue. The hypertension renal denervation trial is expected to finish enrolling in 2026.
